Current Studies

Current Studies - Recruiting

• NCT05575492: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
  Sponsor: ModernaTX, Inc.
  Principal Investigator: Richard Rupp, MD
  
  For more information click  here

Current Studies - Active, Not Recruiting

• NCT04708041: Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT04642079: Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
  For more information, please visit www.nexxstep14study.com
  or contact  Robert Cox, RN 409-772-5278 sivsctp@utmb.edu
  
  Sponsor: Pfizer Inc.
  Principal Investigator: Richard Rupp, MD
  
  For clinicaltrials.gov information, click here 
• NCT04525599: A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
  For more information, please visit www.VaccineStudyForKids.com
  or contact  Robert Cox, RN 409-772-5278 or sivsctp@utmb.edu
  
  Sponsor: Astellas Pharma Global Development Inc. (APGD)
  Principal Investigator: Richard Rupp, MD
  
  For clinicaltrials.gov information, click here
   
• NCT04470427: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
  Sponsor: ModernaTX, Inc.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT04368728: Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
  Sponsor: Pfizer Inc.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT04199689: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT04144348: Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure
  Sponsor: ModernaTX, Inc.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
   
• NCT03893448: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PNEU-PED)

  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator (Galveston): Richard Rupp, MD
  Principal Investigator (Bay Colony): Marcela Navarro, MD
  
  For more information click here

    
• NCT03738241: A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered IM With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT03692871: A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Marcela Navarro, MD
  
  For more information click here
• NCT03682120: A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant
  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT03620162: A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Richard Rupp, MD 
  
  For more information click here
• NCT03537508: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
  Sponsor: Sanofi Pasteur 
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT03524118: A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Richard Rupp, MD 
  For more information click here
   
• NCT03512288: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants (B747-1003)
  Sponsor: Pfizer Inc.      
  Principal Investigator: Richard Rupp, MD
  
  For more information click here
• NCT03486834: Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

  Sponsor: Merck Sharp & Dohme Corp 
  Principal Investigator: Richard Rupp, MD
  
  For more information click here

• NCT03480763: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

  Sponsor: Merck Sharp & Dohme Corp.
  Principal Investigator: Richard Rupp, MD 
  
  For more information click here

• NCT03090191: A phase III, placebo-controlled, randomized, observer-blinded, study to evaluate efficacy, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older (CLOVER)

  Sponsor: Pfizer Inc.   
  Principal Investigator: Richard Rupp, MD
  
  For more information click here

• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults
  Sponsor: Pfizer Inc.
  Principal Investigator: Richard Rupp, MD
  
  For more information click here